urantide对动脉粥样硬化大鼠血钙、血脂和心肌酶学指标的影响

doi:10.13481/j.1671-587x.20190220

吉林大学学报(医学版) ›› 2019, Vol. 45 ›› Issue (02): 331-335.doi: 10.13481/j.1671-587x.20190220

• 基础研究 • 上一篇

urantide对动脉粥样硬化大鼠血钙、血脂和心肌酶学指标的影响

孙晓旭¹, 王途¹, 崔海鹏¹, 刘凯¹, 高海成², 赵娟¹

1. 承德医学院病理生理学教研室, 河北承德 067000;
2. 吉林大学药学院临床药学教研室, 吉林长春 130021

收稿日期:2018-07-09 发布日期:2019-03-29
通讯作者: 赵娟,教授,硕士研究生导师(Tel:0314-2291364,E-mail:zhaojuan811015@sina.com) E-mail:zhaojuan811015@sina.com
作者简介:孙晓旭(1992-),女,河北省张家口市人,在读医学硕士,主要从事动脉粥样硬化分子病理学方面的研究。
基金资助:
河北省青年拔尖人才项目资助课题（冀组字（2016）9号）；河北省教育厅优秀青年基金项目资助课题（YQ2013005）；河北省高校重点学科建设项目资助课题（冀教高（2013）4号）；吉林省科技厅科研基金资助课题（20170204027YY）

Effects of urantide on serum calcium, blood lipids and indexes of myocardial enzymes in rats with atherosclerosis

SUN Xiaoxu¹, WANG Tu¹, CUI Haipeng¹, LIU Kai¹, GAO Haicheng², ZHAO Juan¹

1. Department of Pathophysiology, Chengde Medical University, Chengde 067000, China;
2. Department of Clinical Pharmacy, School of Pharmacy, Jilin University, Changchun 130021, China

Received:2018-07-09 Published:2019-03-29

摘要/Abstract

摘要： 目的：探讨urantide对动脉粥样硬化（AS）大鼠血钙、血脂和心肌酶学指标的影响，阐明其防治AS的作用机制。方法：选取180只Wistar大鼠，随机分为正常对照组、AS组、阳性药（辛伐他汀）组和urantide组（3、7和14 d组），每组30只。采用腹腔注射维生素D₃（VD₃）和高脂饲料喂养的方法建立大鼠AS模型。各组大鼠在实验前、用药前和实验结束时分别称体质量，并应用全自动生化分析仪检测各组大鼠血清中Ca²⁺、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）、肌酸激酶（CK）和乳酸脱氢酶（LDH）水平。结果：正常对照组大鼠体质量随着饲养时间的延长而增加；与正常对照组比较，AS组大鼠用药前体质量明显降低（P<0.01）；与AS组比较，各给药组大鼠给药后体质量不同程度增加（P<0.05或P<0.01）。与正常对照组比较，AS组大鼠血清中Ca²⁺、TC、TG、LDL、CK和LDH水平均明显升高（P<0.01），而HDL水平则明显降低（P<0.01）；与AS组比较，urantide组大鼠血清中Ca²⁺、TC、TG、LDL、CK和LDH水平均明显降低（P<0.05或P<0.01），而HDL水平升高（P<0.05或P<0.01）。结论：urantide可通过下调或上调AS大鼠血清中Ca²⁺、血脂和心肌酶学指标水平而起到防治AS的作用。

关键词: urantide, 动脉粥样硬化, 血钙, 血脂, 肌酸激酶, 乳酸脱氢酶

Abstract: Objective: To investigate the effect of urantide on the levels of serum calcium, blood lipids and indexes of myocardial enzymes in the rats with atherosclerosis(As), and to clarify its mechanism of prevention and treatment of AS.Methods: A total of 180 Wistar rats were selected and randomly divided into normal control group, AS group, positive drug (simvastatin) group and urantide groups (3, 7 and 14 d group), 30 rats in each group. The rat model of AS was established by feeding on high-fat diet or intraperitoneally injecting vitamin D₃(VD₃).The body weights of rats were weighed at three time points: pre-experiment, pre-administration and end of experiment. The levels of Ca²⁺, total cholesterol(TC), triglyceride(TG), low density lipoprotein(LDL), high density lipoprotein(HDL), creatine kinase(CK) and lactic dehydrogenase(LDH) in the serum of the rats in various groups were detected by automatic biochemical analyzer.Results: The body weights of the rats in normal control group were gradually decreased with the prolongation of time;compared with normal control group, the body weights of the rats in AS group at the time point of pre-administration was decreased(P<0.01);compared with AS group, the body weights of the rats in different administration groups were increased(P<0.05 or P<0.01).The levels of serum Ca²⁺, TG, TC, LDL, CK and LDH of the rats in AS group were significantly higher than those in normal control group, and the level of HDL was decreased significantly(P<0.01).Compared with AS group, the levels of serum Ca²⁺, TC, TG, LDL, CK and LDH of the rats in urantide group were significantly decreased(P<0.05 or P<0.01), while the HDL levels were higher (P<0.05 or P<0.01).Conclusion: Urantide can prevent and treat AS by down-regulating or up-regulating the levels of serum calcium, blood lipids and indexes of myocardial enzymes in the AS rats.

Key words: urantide, atherosclerosis, serum calcium, blood lipids, creatine kinase, lactate dehydrogenase

中图分类号:

R363.1

孙晓旭, 王途, 崔海鹏, 刘凯, 高海成, 赵娟. urantide对动脉粥样硬化大鼠血钙、血脂和心肌酶学指标的影响[J]. 吉林大学学报(医学版), 2019, 45(02): 331-335.

SUN Xiaoxu, WANG Tu, CUI Haipeng, LIU Kai, GAO Haicheng, ZHAO Juan. Effects of urantide on serum calcium, blood lipids and indexes of myocardial enzymes in rats with atherosclerosis[J]. Journal of Jilin University(Medicine Edition), 2019, 45(02): 331-335.

参考文献

[1] TORRES N, GUEVARA-CRUZ M, VELAZQUEZ-VILLEGAS L A, et al. Nutrition and Atherosclerosis[J]. Arch Med Res, 2015, 46(5):408-426.
[2] MITRA R, ONEIL G L, HARDING I C, et al. Glycocalyx in atherosclerosis-relevant endothelium function and as a therapeutic target[J]. Curr Atheroscler Rep, 2017, 19(12):63.
[3] YAO Z. Frontiers in atherosclerosis, heart disease and diabetes[J]. Cardiovasc Hematol Disord Drug Targets, 2014, 14(2):87-88.
[4] ZHAO J, YU QX, KONG W, et al. The urotensin Ⅱ receptor antagonist, urantide, protects against atherosclerosis in rats[J]. Exp Ther Med, 2013, 5(6):1765-1769.
[5] LU R, YUAN T, WANG Y, et al. Spontaneous severe hypercholesterolemia and atherosclerosis lesions in rabbits with deficiency of low-density lipoprotein receptor(LDLR) on exon 7[J]. EBioMedicine, 2018, 36:29-38.
[6] MICKIEWICZ A, BOROWIEC-WOLNA J, BACHORSKI W, et al. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy:Three year experience at a lipoprotein apheresis centre[J]. Cardiol J, 2018, 9(7):1-23.
[7] CAO F, ZERVOU S, LYQATE C A. The creatine kinase system as a therapeutic target for myocardial ischaemia-reperfusion injury[J]. Biochem Soc Trans, 2018, 46(5):1119-1127.
[8] 赵娟,宋成军,姜菊花,等.Urantide对实验性动脉粥样硬化大鼠肝脏的影响[J].中国老年学杂志,2014,34(4):940-942.
[9] ZHAO J, XIE L D, SONG C J, et al. Urantide improves atherosclerosis by controlling C-reactive protein, monocyte chemotactic protein-1and transforming growth factor-Urantide improves atherosclerosis by controlling Creactive protein, monocyte chemotactic protein-1 and transforming growth factor-β expression in rats[J]. Therapeut Med, 2014, 7(10):1647-1652.
[10] GUO Y, YUAN W, YU B, et al. Synthetic high-density lipoprotein-mediated targted delivery of liver x receptors agonist promotes atherosclerosis regression[J]. EBioMedicine, 2018, 28:225-233.
[11] KEYAMURA Y, NAQANO C, KOHASHI M, et al. Dietary cholesterol atherogenic changes in juvenile rabbits[J]. Biol Pharm Bull, 2015, 38(5):785-788.
[12] GO G W. Low-density lipoprotein receptor-related protein 6(LRP6) is a novel nutreitional therapeutic target for hyperlipidemia,non-alcohilic, fatty liver disease and atherosclerosis[J]. Nutrients, 2015, 7(6):4453-4464.
[13] SOBENIN I A, SALONEN J T, ZHELANKIN A V, et al. Low density lipoprotein-containing circulating immune complexes:role in atherosclerosis and diagnostic value[J]. Biomed Res Int, 2014, 2014:205697.
[14] HU J, XI D, ZHAO J, et al. High-density lipoprotein and inflammation and its significance to atherosclerosis[J]. Am J Med Sci, 2016, 352(4):408-415.
[15] FEIQ J E, HEWINQ B, SMITH J D, et al. High-density lipoprotein and atherosclerosis regression:evidence from preclinical and clinical studies[J]. Circ Res, 2014, 114(1):205-213.
[16] 江志奎,朱华庆,周青,等.动脉粥样硬化兔模型血液中乳酸脱氢酶和肌酸激酶的动态分析[J].安徽医科大学学报,2004,39(1):12-15.
[17] 马宏昆,张文.动脉粥样硬化性肾动脉狭窄的评估与干预[J].中国实用内科杂志,2018,38(12):1203-1207.
[18] ALEVRIADOU B R, SHANMUGHAPRIYA S, PATEL A, et al. Mitochondrial Ca²⁺ transport in the endotheliun:regulation by ions, redox signaling and mechanical forces[J]. J R Soc Interface, 2017, 14(137):1-15.
[19] SADDOUK F Z, GINNAN R, SINQER H A. Ca²⁺/calmodulin-dependent protein kinase Ⅱ in vascular smooth muscle[J]. Adv Pharmacol, 2017, 78(10):171-202.
[20] TAYLOR M S, CHOI C S, BAYAZID L, et al. Changes in vascular reactivity and endothelial Ca²⁺ dynamics with chronic low flow[J]. Microcirculation, 2017, 24(3):1-24.
[21] SU J, ZHOU H, LIU X, et al. OxLDL antibody inhibits MCP-1 release in monocytes/macrophages by regulating Ca²⁺/K⁺ channel flow[J]. J Cell Mol Med, 2017, 21(5):929-940.
[22] BRYAN R, KATHERINE M, ADEL G. Role of urotensin Ⅱ in health and disease[J]. Am J Physiol Regul Integer Comp Physiol, 2010, 298(5):R1156-R1172.

urantide对动脉粥样硬化大鼠血钙、血脂和心肌酶学指标的影响

Effects of urantide on serum calcium, blood lipids and indexes of myocardial enzymes in rats with atherosclerosis

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	刘晓洁, 梅涛, 麻红艳, 叶山东. 单纯2型糖尿病患者颈动脉粥样硬化斑块形成及其稳定性影响因素分析[J]. 吉林大学学报(医学版), 2018, 44(02): 350-355.
[2]	徐吉光, 李宇宁. 叶酸联合维生素B12对高同型半胱氨酸血症引起大鼠动脉粥样硬化的治疗作用[J]. 吉林大学学报(医学版), 2017, 43(05): 943-947.
[3]	周宏, 刘进才, 罗光华, 谢佩含, 杨娟, 董宇岚, 卿伟鹏, 张晶晶. 冠状动脉疾病报告与数据系统在冠心病患者危险因素分析中的应用[J]. 吉林大学学报(医学版), 2017, 43(03): 617-622.
[4]	陈欢雪, 王晓非. 吸烟对男性类风湿关节炎患者血脂水平和疾病活动度影响的病例对照研究[J]. 吉林大学学报(医学版), 2017, 43(02): 356-360.
[5]	刘洋, 怀施涛, 付文博, 宋亚芹, 卢沐, 庞丽娟, 魏育涛. 冠心病伴心外膜脂肪增厚大鼠模型的制备[J]. 吉林大学学报(医学版), 2017, 43(01): 176-180.
[6]	王云飞, 司道远, 杨萍. 指尖光学体积描记法检测血管内皮功能在冠心病患者筛查中的应用[J]. 吉林大学学报(医学版), 2016, 42(05): 1014-1018.
[7]	吕文轩, 范思佳, 李文耀, 于景文, 陈丽娟, 邓悦. 参红通络颗粒对ApoE^-/-小鼠动脉粥样硬化斑块内细胞凋亡的影响及其抗动脉粥样硬化作用机制[J]. 吉林大学学报(医学版), 2016, 42(05): 882-886.
[8]	麦莉, 韦建瑞, 华兴. IRF5基因慢病毒表达载体的构建及其在巨噬细胞RAW264.7中的表达[J]. 吉林大学学报(医学版), 2016, 42(03): 452-456.
[9]	吕文轩, 李文耀, 范思佳, 赵殊, 郭五虎, 陈丽娟, 邓悦. 瑞舒伐他汀对载脂蛋白E基因敲除小鼠动脉粥样硬化的治疗作用及其机制[J]. 吉林大学学报(医学版), 2016, 42(02): 240-244.
[10]	孙丽娟, 刘婷, 徐秀梅, 李杰. 瑞舒伐他汀治疗老年人下肢动脉粥样硬化的效果评价[J]. 吉林大学学报(医学版), 2015, 41(06): 1260-1263.
[11]	石美荣, 姜薇, 王志远, 石卫东, 孙若雪, 陈恩琪, 刘美含. 颈动脉和下肢动脉粥样硬化的超声检查及其危险因素分析[J]. 吉林大学学报(医学版), 2015, 41(05): 1055-1059.
[12]	傅倩晰, 周莉, 唐敏, 张名均, 唐晓君. 男性人群中载脂蛋白E基因多态性与血脂水平的关联性分析[J]. 吉林大学学报(医学版), 2015, 41(04): 808-813.
[13]	. 阿托伐他汀对同型半胱氨酸作用下人脐静脉内皮细胞Bcl-2启动子区甲基化水平的影响及其抗动脉粥样硬化机制[J]. 吉林大学学报(医学版), 2014, 40(05): 1002-1006.
[14]	马丹,谢晓娜,邹敬韬,刘玉佳,孙中华,高影. 黄芪注射液对糖尿病大鼠肾脏的保护作用及其机制[J]. 吉林大学学报(医学版), 2014, 40(02): 271-275.
[15]	赵铁柱，沈焕，陶致侃，王为，赵丹丹. 洛伐他汀对TNF-α诱导人脐静脉内皮细胞MCP-1和IL-10表达的影响[J]. 吉林大学学报(医学版), 2013, 39(5): 928-932.